Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States

Bijal Shah, Mei Xue, Wesley Furnback, Kaitlyn Esselman, Po‐Ya Chuang, Keri Yang

Open source

DOI
10.1002/hon.70201
Published
2026-05
Container
Hematological Oncology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/hon.70201,
  title = {Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States},
  author = {Bijal Shah and Mei Xue and Wesley Furnback and Kaitlyn Esselman and Po‐Ya Chuang and Keri Yang},
  year = {2026},
  journal = {Hematological Oncology},
  doi = {10.1002/hon.70201},
  url = {https://doi.org/10.1002/hon.70201}
}

RIS

TY  - JOUR
TI  - Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States
AU  - Bijal Shah
AU  - Mei Xue
AU  - Wesley Furnback
AU  - Kaitlyn Esselman
AU  - Po‐Ya Chuang
AU  - Keri Yang
PY  - 2026
JO  - Hematological Oncology
DO  - 10.1002/hon.70201
UR  - https://doi.org/10.1002/hon.70201
ER  - 

APA

Shah, B., Xue, M., Furnback, W., Esselman, K., Chuang, P., & Yang, K. (2026). Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States. Hematological Oncology. https://doi.org/10.1002/hon.70201

Source records